A new diagnostic membrane enables fast, sharp line separation and reproducible results for the detection of target molecules in liquids such as water, urine, blood, and saliva. The target molecules can be drugs, hormones, proteins, antibodies, nucleic acids, bacteria, and viruses.

The Whatman FF High-Performance (HP) membrane was launched by GE Healthcare Life Sciences (Little Chalfont, United Kingdom) and is suitable for use in the manufacture of lateral flow assays. A new casting method used to produce the membrane yields a uniform, powder-free surface that delivers a coefficient of variation in capillary rise of < 10%.

The intra- and inter-lot consistency of the new membrane was tested through analysis of more than 1,000 samples and produced a low coefficient of variation. The reproducibility of the analysis improves the consistency of assays and offers a reliable limit of detection, which in turn reduces the costs of assay optimization for scientists.

Three FF HP membranes are currently available with different capillary rise times allowing researchers to choose the most suitable membrane for their assay.

In addition to immunoassays, molecular assays, and sample collection devices, GE Healthcare provides custom components for a variety of uses and applications such as in-line filters for anesthesia instruments, blood purification, and track-etched membranes.

Related Links:
GE Healthcare Life Sciences